Synergistic interactions of etoposide and interleukin-1α are not due to DNA damage in human melanoma cells
- 22 January 1993
- journal article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1180 (3) , 231-235
- https://doi.org/10.1016/0925-4439(93)90043-z
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Structure-activity relations, cytotoxicity and topoisomerase II dependent cleavage induced by pendulum ring analogues of etoposideEuropean Journal of Cancer and Clinical Oncology, 1990
- Synergistic Antitumor Activity of Etoposide and Human Interleukin-1 Against Human Melanoma CellsJNCI Journal of the National Cancer Institute, 1989
- Mechanism of Action of Antitumor Drug Etoposide: A ReviewJNCI Journal of the National Cancer Institute, 1988
- In vitro metabolism of etoposide (VP-16-213) by liver microsomes and irreversible binding of reactive intermediates to microsomal proteinsBiochemical Pharmacology, 1987
- Mechanism of in vitro Antitumor Effects of Interleukin 1 (IL 1)Immunobiology, 1986
- Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavageBiochemical Pharmacology, 1985
- Etoposide (VP-16–213)New England Journal of Medicine, 1985
- Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationshipBiochemistry, 1984
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984